Uncover key drivers, emerging technologies, and competitive movements shaping the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market from 2025–2034 with trusted insights from The Business Research Company
What Are The Market Size Estimates For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Now And By 2029?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has experienced significant growth over recent years. It is projected to expand from $5.69 billion in 2024 to $6.11 billion in 2025, at a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to the increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, and rising global healthcare access.
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is anticipated to expand significantly in the upcoming years. It is projected to reach $8.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.7%. The expansion during this forecast period is attributable to aspects like telemedicine and remote monitoring, data analytics and AI, patient education and support, as well as changes in regulatory and reimbursement policies. Noteworthy trends for the forecast period include personalized treatment approaches, the development of new therapies, minimally invasive diagnostics, and collaborative care models.
Access A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Which Long-Term Drivers Are Expected To Sustain The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The growing population affected by diabetes is anticipated to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is defined as a long-term metabolic condition marked by elevated blood sugar levels (hyperglycemia) extending over an extended duration, arising from the body’s deficiency in producing sufficient insulin or its ineffective utilization of the insulin it generates. Pancreatic enzyme replacement therapy (PERT), central to EPI treatment, can facilitate better nutrient absorption for individuals experiencing both diabetes and EPI, and additionally, it can contribute to enhanced glycemic control in diabetic patients. As an illustration, data released in June 2024 by The National Health Service (NHS England), a publicly funded healthcare system in the UK, revealed that in 2023, the count of individuals identified by the NHS in England with pre-diabetes climbed to 3,615,330. This represented an 18% surge from the 3,065,825 recorded in 2022. Furthermore, cases among those aged under 40 experienced a near 25% increase, rising from 173,166 in 2022 to 216,440 in 2023. Consequently, the expanding population affected by diabetes is propelling the advancement of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
How Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Classified By Different Segments?
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
What Current And Upcoming Trends Are Shaping The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Key companies within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly adopting a strategic partnership model to improve technology integration and expand their market presence. A strategic partnership generally signifies a cooperative arrangement between multiple organizations that combine their resources, expertise, and efforts to achieve common objectives. For example, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition company, disclosed interim results from their Phase 1 clinical trial involving CDX-7108, an investigational therapy developed for treating exocrine pancreatic insufficiency (EPI). The outcomes of this Phase 1 trial lay the groundwork for future studies that could significantly enhance treatment possibilities for individuals living with EPI.
Who Are The Primary Market Leaders In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
Download The Full Report Here:
Which Regional Markets Are Emerging As Key Centers For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get A Report Customized For You Here:
https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2025, By The Business Research Company
Inflammatory Bowel Disease Treatment Global Market Report 2025
Irritable Bowel Syndrome Ibs Treatment Global Market Report 2025
Gastric Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model